产品
编 号：F306080
分子式：C59H105N17O11
分子量：1228.57
分子式：C59H105N17O11
分子量：1228.57
产品类型
规格
价格
是否有货
结构图
CAS No: 287096-87-1
产品详情
生物活性：
Delmitide (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide can be used for the research of ulcerative colitis.
体内研究：
Delmitide (oral; 2.5, 5, 10 mg/kg; daily) significantly reduced CPT-11induced diarrhea, mucosal inflammation, and mortality in mice by suppressing the overproduction of proinflammatory cytokines TNF-a, IFN-y, and IL-12 in vivo.Delmitide (oral; 2.5, 5, 10 mg/kg; daily) generates an enhanced tumor response and prolongation of time to relapse without concomitant Gl toxicity in mice.Animal Model:BALB/c mice (female, 9-10-week)
Dosage:2.5, 5, 10 mg/kg or 0.2 mL, 10 mg/kg
Administration:Oral, daily
Result:Reduced the incidence of diarrhea and attenuated CPT-11-associated GI toxicity and mortality in a dose-dependent manner.Had protective effect against chemotherapy-induced GI side-effects and reduced CPT-11-induced overexpression of TNF-α, IFN-γ, and IL-12 in vivo.Preserved the intestinal mucosa morphology by maintaining villus and crypt structure and inhibited TNF-α-mediated apoptosis in the crypt compartment, thereby protecting intestinal mucosa integrity in mice.Protected mice from CPT-11-induced GI toxicity and mortality and enhanced animal survival in tumor-bearing mice.Significantly reduced the incidence and overall tumor burden in a spontaneously metastatic model.
Delmitide (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide can be used for the research of ulcerative colitis.
体内研究：
Delmitide (oral; 2.5, 5, 10 mg/kg; daily) significantly reduced CPT-11induced diarrhea, mucosal inflammation, and mortality in mice by suppressing the overproduction of proinflammatory cytokines TNF-a, IFN-y, and IL-12 in vivo.Delmitide (oral; 2.5, 5, 10 mg/kg; daily) generates an enhanced tumor response and prolongation of time to relapse without concomitant Gl toxicity in mice.Animal Model:BALB/c mice (female, 9-10-week)
Dosage:2.5, 5, 10 mg/kg or 0.2 mL, 10 mg/kg
Administration:Oral, daily
Result:Reduced the incidence of diarrhea and attenuated CPT-11-associated GI toxicity and mortality in a dose-dependent manner.Had protective effect against chemotherapy-induced GI side-effects and reduced CPT-11-induced overexpression of TNF-α, IFN-γ, and IL-12 in vivo.Preserved the intestinal mucosa morphology by maintaining villus and crypt structure and inhibited TNF-α-mediated apoptosis in the crypt compartment, thereby protecting intestinal mucosa integrity in mice.Protected mice from CPT-11-induced GI toxicity and mortality and enhanced animal survival in tumor-bearing mice.Significantly reduced the incidence and overall tumor burden in a spontaneously metastatic model.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备